Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment
Open Access
- 9 October 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 124 (15), 2467-2468
- https://doi.org/10.1182/blood-2014-06-583302
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapyNature Reviews Gastroenterology & Hepatology, 2014
- Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trialThe Lancet, 2013
- Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)Blood, 2013
- Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancerGut, 2011
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statementLeukemia, 2011
- The Bile Acid Turnover Rate Assessed with the 75SeHCAT Test Is Stable in Chronic Diarrhoea but Slightly Decreased in Healthy Subjects After a Long Period of TimeDigestive Diseases and Sciences, 2008
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005